Literature DB >> 19327598

Managing patients with chronic severe asthma: rise to the challenge.

Riccardo Polosa1, Giuseppe Trifoglio Benfatto.   

Abstract

Most asthmatic patients with moderate to severe disease can be satisfactorily managed with a combination of inhaled corticosteroids and beta(2)-agonists. However, there are perhaps 10% of the asthmatic population with persistent symptoms, impaired quality of life and excessive health-care utilization, despite this management regime. These patients often require frequent and even occasionally regular oral corticosteroid use. Chronic, severe asthma is a heterogeneous disease with distinct sub-phenotypes. A systematic diagnostic work-up may help to identify these distinct sub-phenotypes and this may help guide treatment and may even provide information about prognosis. Optimal treatment of chronic severe asthma should achieve the best possible asthma control and quality of life with the least dose of systemic corticosteroids. The choice and formulation of therapeutic agent is dictated by the severity of disease and includes conventional, immunosuppressive/immunomodulating and biologic therapies. Unfortunately, current asthma management guidelines offer little contribution to the care of the challenging patient with chronic severe asthma. This review article aims at summarizing the evidence regarding various therapeutic modalities for chronic severe asthma and also aims to provide a practical approach to diagnosis and management for the benefit of those who have a specific interest in this problematic condition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19327598     DOI: 10.1016/j.ejim.2008.06.010

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

1.  Extrafine HFA-beclomethasone dipropionate versus budesonide for asthma: a meta-analysis.

Authors:  Xin Chen; Yingbo Kang; Liqing Wang; Lin Lin; Zhe Zhu; Rui Chen
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Identification of subtypes of refractory asthma in Korean patients by cluster analysis.

Authors:  An Soo Jang; Hyouk-Soo Kwon; You Sook Cho; Yun Jeong Bae; Tae Bum Kim; Jong Sook Park; Sung Woo Park; Soo-Taek Uh; Jae-Sung Choi; Yong-Hoon Kim; Hyeon-Kyu Hwang; Hee-Bom Moon; Choon Sik Park
Journal:  Lung       Date:  2012-11-10       Impact factor: 2.584

Review 3.  Monoclonal antibodies for the treatment of severe asthma.

Authors:  Salvatore Clienti; Jaymin B Morjaria; Elisa Basile; Riccardo Polosa
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

4.  Unusual asthma syndromes and their management.

Authors:  Jaymin B Morjaria; Jack A Kastelik
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

Review 5.  Stratified approaches to the treatment of asthma.

Authors:  Stephen T Holgate
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

6.  Recommendation for optimal management of severe refractory asthma.

Authors:  Jaymin B Morjaria; Riccardo Polosa
Journal:  J Asthma Allergy       Date:  2010-07-26

7.  The Advance of Personalized and Stratified Therapies in Bronchial Asthma: Phenotypes - Endotypes - Biomarkers.

Authors:  Sebastian Lauer; Harald Renz
Journal:  EJIFCC       Date:  2013-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.